The PIB release is a useful business signal for ISO 10993 consulting because it explicitly connects India's medical-device parks with shared testing and validation infrastructure, including biocompatibility testing and toxicology.
That does not remove the need for a defensible BEP, BER, TRA, or submission narrative. It makes early documentation planning more important, because access to testing facilities only helps when the test strategy and regulatory argument are well designed.
On 13 February 2026, India's Press Information Bureau published an update on the medical devices sector covering PLI-supported manufacturing, medical-device parks, skill development, and PRIP-backed R&D support. For MedDev Advisory's audience, the most important part is not only that India is investing in manufacturing. It is that the release names the exact infrastructure that tends to expose weak biological-evaluation planning: sterilization, biocompatibility testing, toxicology, 3D design and printing, and validation facilities.
What the PIB Release Says
The release describes Medical Device Parks in Uttar Pradesh, Madhya Pradesh, and Tamil Nadu as part of an effort to build a more competitive domestic manufacturing ecosystem. It also explains that shared facilities can reduce the need for each company to invest separately in expensive infrastructure.
For medical-device startups and greenfield manufacturers, that is meaningful. Access to common facilities can reduce cost and shorten development timelines. But it can also create a false sense of readiness if the team assumes testing access is the same as regulatory readiness.
Why This Matters for ISO 10993
Biocompatibility is not just a laboratory purchase order. Under ISO 10993, the biological evaluation starts with device characterization, contact classification, endpoint selection, evidence planning, and risk-based justification. Testing is only one part of that system.
If a startup uses shared testing facilities without a clear Biological Evaluation Plan, the result may be a collection of reports that still does not answer the reviewer's actual question: why is this finished device biologically safe for its intended use?
Where Startups Can Lose Time
- Testing before endpoint strategy: ordering tests before contact type, contact duration, materials, and intended use are correctly mapped.
- Finished-device mismatch: testing a material, prototype, or non-final configuration that does not represent the device to be submitted.
- Sterilization not integrated: treating sterilization as a production step without assessing how it changes residues, chemistry, or biological risk.
- Toxicology disconnected from chemistry: generating chemical data without a clear TRA plan or endpoint-waiver logic.
- India-only framing: building documentation only for CDSCO when the commercial plan may later require FDA 510(k), EU MDR, or international investor diligence.
What Companies Should Prepare Before Testing
Before using a common biocompatibility or toxicology facility, teams should usually have at least a lightweight ISO 10993 strategy. That does not need to be overbuilt, but it should be specific enough to prevent avoidable rework.
- Device and contact classification: tissue or fluid contact type, duration, and patient-contacting materials.
- Preliminary BEP: expected endpoints, existing evidence, proposed testing, and justification for any waivers.
- Sterilization and manufacturing state: whether the test article represents the final cleaned, sterilized, packaged, or aged device.
- Chemistry and TRA plan: whether chemical characterization and toxicological risk assessment are needed before, after, or instead of some biological tests.
- Target pathway: CDSCO only, CDSCO plus FDA, CDSCO plus EU MDR, or an investor-facing evidence package.
Shared testing infrastructure helps only when the test plan is tied to a defensible regulatory argument. The strongest companies will use medical-device parks to accelerate evidence generation, not to skip biological evaluation strategy.
How This Creates a Lead-Generation Opportunity
For MedDev Advisory, this update creates a clear outreach angle: manufacturers entering or working around India's medical-device manufacturing ecosystem may need specialist support before they invest in testing. The useful offer is not generic consulting. It is a focused ISO 10993 gap review or BEP/BER/TRA planning scope for teams preparing Indian, US, or EU-facing documentation.
A strong first message to a startup is simple: if you are preparing to use biocompatibility, toxicology, sterilization, or validation facilities, check whether your ISO 10993 plan will produce submission-ready evidence before the work begins.
Best Next Step
For early-stage companies, the safest next step is usually a short documentation and test-strategy review. For companies already holding test reports, the best next step is often a BER or submission gap review to determine whether the existing evidence can support the intended regulatory pathway.
Why this matters to MedDev Advisory clients
MedDev Advisory focuses on ISO 10993 biological evaluation, BEP and BER documentation, toxicological risk assessment, FDA 510(k) biocompatibility sections, EU MDR technical-file support, and India / CDSCO strategy work. The practical value is translating infrastructure and policy signals into submission-ready documentation decisions. Read more about Arvind Rathore.
Use infrastructure momentum, but do not let testing outrun the regulatory strategy.
If your team is preparing biocompatibility, toxicology, sterilization, or validation work, a short ISO 10993 planning review can prevent expensive rework later.